11 studies found for:    G250
Show Display Options
Rank Status Study
1 Terminated Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: G250 peptide;   Drug: IL-2
2 Unknown  Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250
Conditions: Renal Cell Carcinoma;   Kidney Neoplasm;   Renal Cancer;   Kidney Cancer
Intervention: Drug: Yttrium-90 conjugated chimeric G250 (90Y-cG250)
3 Completed
Has Results
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
Conditions: Renal Cell Carcinoma;   Kidney Cancer
Interventions: Drug: 124-Iodine-cG250 (124I-cG250);   Procedure: CT
4 Completed Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
Condition: Kidney Cancer
Intervention: Radiation: iodine I 131 chimeric monoclonal antibody G-250
5 Completed Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: girentuximab;   Other: placebo
6 Completed Brivanib Metastatic Renal Cell Carcinoma
Condition: Male and Female Subjects 18 Years of Age and Older With Metastatic Renal Cell Carcinoma. Eligible Patients Must Have Undergone and Failed Prior Treatment.
Interventions: Drug: Brivanib alaninate;   Genetic: Polymerase chain reaction;   Other: Iodine I 124 chimeric monoclonal antibody G250;   Procedure: Positron emission tomography/computed tomography;   Genetic: Protein expression analysis;   Other: Immunohistochemistry
7 Completed Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
Conditions: Cancer of Kidney;   Kidney Cancer;   Renal Cancer;   Neoplasms, Kidney;   Renal Neoplasms
Intervention: Drug: 124-Iodine-cG250 (124I-cG250)
8 Completed Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: Sorafenib;   Drug: 111Indium-bevacizumab;   Drug: 111Indium-cG250
9 Terminated Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer
Conditions: Metastatic Kidney Cancer;   Metastatic Renal Cell Carcinoma
Intervention: Other: Serum and urinary CA9 level
10 Terminated Study of Safety and Effects of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Biological: Chimeric monoclonal antibody cG250;   Drug: Sunitinib malate
11 Recruiting Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Condition: Renal Cancer
Intervention: Drug: 124IcG250

Indicates status has not been verified in more than two years